ArticleKidney cancer journal : official journal of the Kidney Cancer Association2025
Urine C-reactive protein content and non-invasive molecular grading of renal cell carcinoma.
Article in Kidney cancer journal : official journal of the Kidney Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter Analysis.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
C-reactive protein may be overexpressed in kidney cancer tissue. We determined if urine C-reactive protein concentration is greater in patients with high grade renal cell carcinoma or greater than healthy controls, and compared to other urologic cancers and non-cancerous urologic disease. This observational study obtained pre-nephrectomy urine and plasma from 87 patients with a small imaged renal mass (≤4cm) undergoing partial nephrectomy. Postoperative pathology established clear cell or papillary renal cell cancer, angiomyolipoma, chromophobe, or oncocytoma, and tumor Fuhrman grade. Follow-up urine was collected from 52 clear cell/papillary cancer patients. Urine and/or plasma were from bladder or prostate cancer patients and matched healthy controls. C-reactive protein was measured by enzyme-linked immunosorbent assay. Urine C-reactive protein in grade 1-2 (n=41) and grade 3-4 (n=24) renal cancer was 17- and 80-fold greater than controls, respectively. This decreased 85% post-nephrectomy, suggesting origin from tumors and not systemic filtration from blood. Urine C-reactive protein in angiomyolipoma, chromophobe, or oncocytoma, bladder or prostate cancer was less than grade 3-4 renal cancer. C-statistic to differentiate grade 1-2 from 3-4 clear cell/papillary renal cancer was 0.98 (95% CI 0.95-1.00); sensitivity 1.00 (95% CI, 0.87-1.00), specificity 0.95 (95% CI 0.84-0.99). Two patients with remarkably high pre-nephrectomy urine C-reactive protein, but no others, developed late metastases. Pre-nephrectomy urine C-reactive protein was increased in patients with high grade clear cell and papillary renal cancer, but not other renal or urologic disease. Urine C-reactive protein may be used pre-surgically to noninvasively grade small renal masses, and may predict future renal cell cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.